Hilltop Holdings Inc. Takes $575,000 Position in Becton Dickinson and Co (BDX)

Share on StockTwits

Hilltop Holdings Inc. purchased a new position in Becton Dickinson and Co (NYSE:BDX) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,655 shares of the medical instruments supplier’s stock, valued at approximately $575,000.

Other large investors have also modified their holdings of the company. Amica Retiree Medical Trust increased its holdings in Becton Dickinson and by 325.0% in the 4th quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after buying an additional 390 shares during the period. Almanack Investment Partners LLC. acquired a new position in Becton Dickinson and in the 4th quarter worth approximately $109,000. Advisors Preferred LLC acquired a new position in Becton Dickinson and in the 4th quarter worth approximately $126,000. Truewealth LLC acquired a new position in Becton Dickinson and in the 4th quarter worth approximately $133,000. Finally, Wagner Wealth Management LLC acquired a new position in Becton Dickinson and in the 4th quarter worth approximately $154,000. Institutional investors own 84.26% of the company’s stock.

In other news, EVP Nabil Shabshab sold 10,209 shares of the stock in a transaction that occurred on Friday, May 11th. The stock was sold at an average price of $226.10, for a total transaction of $2,308,254.90. Following the transaction, the executive vice president now owns 12,476 shares in the company, valued at approximately $2,820,823.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director David F. Melcher bought 500 shares of the firm’s stock in a transaction dated Monday, May 7th. The shares were acquired at an average price of $225.07 per share, for a total transaction of $112,535.00. Following the transaction, the director now directly owns 2,728 shares in the company, valued at $613,990.96. The disclosure for this purchase can be found here. Company insiders own 1.00% of the company’s stock.

BDX has been the topic of several research reports. Citigroup upgraded shares of Becton Dickinson and from a “neutral” rating to a “buy” rating and increased their price target for the stock from $237.00 to $251.00 in a report on Tuesday, April 10th. ValuEngine lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Tuesday, May 29th. Zacks Investment Research lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Tuesday, March 6th. Finally, BMO Capital Markets started coverage on Becton Dickinson and in a research report on Monday, March 5th. They issued a “market perform” rating and a $249.00 price objective on the stock. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $241.19.

Becton Dickinson and opened at $232.16 on Friday, MarketBeat Ratings reports. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.12 and a current ratio of 1.70. Becton Dickinson and Co has a 12 month low of $190.60 and a 12 month high of $248.39. The company has a market capitalization of $62.03 billion, a price-to-earnings ratio of 23.24, a P/E/G ratio of 1.62 and a beta of 1.12.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, May 3rd. The medical instruments supplier reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.63 by $0.02. Becton Dickinson and had a positive return on equity of 14.27% and a negative net margin of 0.46%. The firm had revenue of $4.22 billion for the quarter, compared to analyst estimates of $4.12 billion. During the same quarter last year, the firm posted $2.30 EPS. The business’s revenue was up 42.2% on a year-over-year basis. sell-side analysts expect that Becton Dickinson and Co will post 10.99 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 29th. Stockholders of record on Friday, June 8th will be given a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, June 7th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.29%. Becton Dickinson and’s dividend payout ratio (DPR) is 31.65%.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Analysts Anticipate Trade Desk Inc  Will Post Quarterly Sales of $103.67 Million
Analysts Anticipate Trade Desk Inc Will Post Quarterly Sales of $103.67 Million
Gap Inc  Expected to Announce Quarterly Sales of $3.98 Billion
Gap Inc Expected to Announce Quarterly Sales of $3.98 Billion
Sinovac Biotech  Given Daily Media Impact Rating of -0.02
Sinovac Biotech Given Daily Media Impact Rating of -0.02
Limoneira  Receives Daily News Sentiment Rating of 0.06
Limoneira Receives Daily News Sentiment Rating of 0.06
Motorola Solutions  Hits New 1-Year High at $121.69
Motorola Solutions Hits New 1-Year High at $121.69
Vince  Hits New 52-Week High at $20.35
Vince Hits New 52-Week High at $20.35


© 2006-2018 Ticker Report. Google+.